Addition of mitiglinide to pioglitazone monotherapy improves overall glycemic control in Japanese patients with type 2 diabetes: A randomized double blind trial

Endocrine Journal

Volumn 56, Issue 5, 2009, Pages 657-664

  Kaku, Kohei ^a   Tanaka, Shun Ichi ^b   Origasa, Hideki ^c   Kikuchi, Masatoshi ^d   Akanuma, Yasuo ^d  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b Kanazawa Medical Clinic   (Japan)

^c UNIVERSITY OF TOYAMA   (Japan)

^d INSTITUTE FOR ADULT DISEASES   (Japan)

Author keywords

Mitiglinide; Pioglitazone; Randomized double blind trial; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; MITIGLINIDE; PIOGLITAZONE; PLACEBO;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DIET THERAPY; DOUBLE BLIND PROCEDURE; EDEMA; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; JAPANESE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; WEIGHT GAIN;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC DIET; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; ISOINDOLES; MALE; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 69249220222     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K09E-022     Document Type: Article

References (18)

1. Weyer C, Bogardus C, Mott DM, Pratley RE (1999) the natural history of insulin secretory dysfunction and insulin resistance in pathogenesis of type 2 diabetes mellitus. J Clin Invest 104: 787-794. (Pubitemid 29536364)
2. Balkau B, shipley m, Jarrett rJ, Pyörälä K, Pyörälä m, Forhan a, eschwége e (1998) high blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-Year follow-up in the Whitehall study, the Paris Prospective study, and the helsinki Policemen study. Diabetes Care 21: 360-367.
3. decode study group (1999) glucose tolerance and mortality: comparison of WHO and American Diabetes association diagnostic criteria. Lancet 354: 617-621.
4. tominaga m, eguchi h, manaka h, igarashi K, Kato t, sekikawa a (1999) impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. the Funagata diabetes study. Diabetes Care 22: 920-924.
5. monnier L, Lapinski h, colette c (2003) contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients. Diabetes Care 26: 881-885.
6. ohnota h, Koizumi t, tsutsumi n, Kobayashi m, inoue s, sato F (1994) novel rapid- and short-acting hypoglycemic agent, a calcium (2s)-2-benzyl-3- (cis-hexahydro-2-isoindolinylcarbonyl)propionate (Kad-1229) that acts on the sulfonylurea receptor: comparison of effects between Kad-1229 and gliclazide. J Pharmacol Exp Ther 269: 489-495.
7. + channel by a non-sulfonylurea compound Kad-1229 in a pancreatic beta-cell line, min 6 cell. Eur J Pharmacol 269: 293-298.
8. Bakkali-Nadi A, Malaisse-Lagae F, Malaisse WJ (1994) ionophoretic activity of meglitinide analogues. Diabetes Res 27: 61-71.
9. sunaga y, gonoi t, shibasaki t, ichikawa K, Kusama h, yano h, seino s (2001) the effects of mitiglinide (Kad-1229), a new anti-diabetic drug, on atPsensitive K+ channels and insulin secretion: comparison with the sulufonylureas and nateglinide. Eur J Pharmacol 431: 119-125.
10. reimann F, Proks P, ashcroft Fm (2001) effects of mitiglinide (s 21403) on Kir6.2/sur1, Kir6.2/sur2a and Kir6.2/sur2B types of atP-sensitive potassium channel. Br J Pharmacol 132: 1542-1548.
11. Kawamori r, Kadowaki t, onji m, seino y, akanuma Y (2007) Hepatic safety profile and glycemic control of pioglitazone in more than 20,000 patients with type 2 diabetes mellitus: postmarketing surveillance study in Japan. Diabetes Res Clin Pract 2007; 76: 229-235.
12. dormandy Ja, charbonnel B, eckland dJa, erdmann e, massi-Benedetti m, moules iK, skene am, tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, heine rJ, Korányi L, Laakso m, mokán m, norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, schernthaner g, schmitz o, skrha J, smith u, taton J; Proactive investigators (2005) secondary prevention of macrovascular events in patients with type 2 diabetes in the Proactive study (Prospective pioglitazone clinical trial in macrovascular events): a randomized controlled trial. Lancet 366: 1279-1289.
13. american diabetes association (2007) standards of medical care in diabetes - 2007. Diabetes Care 30 (suppl 1): s4-s41.
14. risso a, mercuri F, Quagliaro L, damante g, ceriello a (2001) intermittent high glucose enhances apoptosis in human umbilical vein endothelical cells in culture. Am J Physiol Endocrinol Metab 281: e924-e930.
15. assaloni r, da ros r, Quagliaro L, Piconi L, maier a, Zuodar g, motz e, ceriello a (2005) effects of s21403 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients. Diabetologia 48: 1919-1924.
16. Fonseca V, grunberger g, gupta s, shen s, Foley Je (2003) addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control. Diabetes Care 26: 1685-1690.
17. Jovanovic L, hassman dr, gooch B, Jain r, greco s, Khutoryansky n, hale Pm (2004) treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone. Diabetes Res Clin Pract 63: 127-134.
18. rosenstock J, gatlin mr, shen sg, Foley Je (2002) combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes. Diabetes Care 25: 1529-1533.